CD68 and ductal breast carcinoma in situ: Clinical research assessing specific subsets of immune cells in DCIS has indicated that CD68+ macrophages (in particular the M2 macrophages), CD4+ T cells and CD20+ B cells were elevated in the high-grade DCIS cases compared to low [84].